Last update 17 Apr 2025

MB-CART2019.1

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-CD20-anti-CD19 CAR T cells, CD20-CD19-targeting CAR T Cells, DALY II USA
+ [2]
Target
CD19 x CD20
Action
inhibitors
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]
Active Indication
Diffuse Large B-Cell LymphomaChronic Lymphocytic LeukemiaHigh grade B-cell lymphoma+ [6]
Inactive Indication-
Originator Organization
Miltenyi Biotec, Inc.
Active Organization
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartupMiltenyi Biotec BV & Co. KG
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with MB-CART2019.1
NCT06508775
/ RecruitingNot Applicable
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT04844866
/ Active, not recruitingPhase 2
A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
NCT03870945
/ CompletedPhase 1/2
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant B-NHL
100 Clinical Results associated with MB-CART2019.1
Login to view more data
100 Translational Medicine associated with MB-CART2019.1
Login to view more data
100 Patents (Medical) associated with MB-CART2019.1
Login to view more data
100 Deals associated with MB-CART2019.1
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 2
Austria
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Belgium
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Czechia
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
France
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Germany
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Hungary
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Italy
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Lithuania
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Netherlands
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Diffuse Large B-Cell LymphomaPhase 2
Poland
Miltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHStartup
18 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03870945 (ASH 12020 | ASH 22020)
ManualManual
Phase 1
B-Cell Lymphoma
CD19 Positive | CD20 Positive
12
twpevzetgi(kcjxearisa) = CRS grade 1 occurred in 3/6 patients on DL1 and DL2 each, and CRS grade 2 in 2 patients on DL2. swshelczwl (pdclbskdnd )
View more
Positive
05 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free